Drug The Undruggable

AI gives us the competitive advantages of screen speed, scale, and potency.

Without AI we are just scratching the surface of what could be drugged.

Most of the genome is not yet targeted by an approved drug.

The majority of the human genome remains undrugged, representing 96% of all human gene targets. Of the roughly 20 thousand proteins encoded in the human genome, only a little over 750 are targeted by FDA-approved small molecule drugs. About 2-3 thousand have a small molecule or a biologic under development.


More genes with disease evidence are ripe for drug discovery.

About 4 thousand genes have experimental evidence linking them to human disease, but may not yet have enough structural data for traditional drug design. These proteins are ready for de novo drug discovery to be immediately explored with our AI technology, representing a potential 4-fold increase beyond the total number of available FDA-approved drugs existing today.


The rest is uncharted territory for de novo drug discovery.

The remaining human gene targets represent novel biology, and contain the most challenging and most promising future targets for pharma and human health. Our AI technology has demonstrated success unlocking new drug targets with little to no structure or activity data, opening up new avenues for drug discovery. Today, over 14 thousand targets can be pursued to start a project with Atomwise.


With Atomwise...

We are poised to capture the novel and complex biology for better medicines faster.
Jeff Perry, PhD
Professor, University of California, Riverside
A hypothesis on HTRA-1 leads to a promising new drug candidate, and the formation of a new joint-venture company between Atomwise and UC Riverside, called Theia Biosciences, to develop therapies for Age-Related Macular Degeneration (AMD).
It’s an accurate and fast method for doing drug discovery. The AI approach is fairly novel. We would not have been able to achieve the same level of screening without it.
Learn More

Competitive Advantage of Scale & Speed

Future drugs are hidden in an enormously vast chemical space. We solve the most challenging targets by running the largest scale drug screens in history to fully explore this space.

With AtomNet® technology we can screen billions of synthesizable molecules against biological targets in days. Once we find hits, we ship synthesized compounds to our partners within weeks for in-lab screening.

Repurposing Libraries

Thousands of Compounds

Pharma HTS Libraries

Millions of Compounds

AtomNet® Technology Screens Billions of Unique and Orderable Compounds in Days

Proven Success With the Most Challenging Targets

We solve the hardest problems in computer-aided drug design, delivering hits even when there is little-to-no structural data for a target. AtomNet® screens make-on-demand molecules so that our AI results won't send our partners down a synthesis rabbit hole. Our partners receive compounds to test in their lab 2-3 weeks after we complete a virtual screen. We have a history of success, delivering at least one hit validated in laboratory experiments 74% of the time.

Pengda Liu, PhD
Associate Professor, University of North Carolina, Chapel Hill
Pursuing a novel target without disease evidence yields a validated new target for pediatric cancer thanks to our Articificial Intelligence Molecular Screening (AIMS) Awards Program.
… the AI-powered results from Atomwise have aligned well with real-world results generated by medicinal chemistry experts at the university. Even without a real structure, the AI can faithfully capture at least 80 to 90 percent of the key structural features of the target.
Learn More

The Atomwise Advantage

Broadly Applicable

With a 74% overall success rate with the most challenging targets across hundreds of projects spanning every class of protein and disease area.

Technology Advantage

AtomNet® technology uses the world's largest screening library of over 16B+ molecules and is covered by 19 issued patents, and yielding 12 pending patent applications to date.

Expert Team

Our experienced team includes 80% PhD's including structural biology, medicinal chemistry, engineering and drug development.

Learn more about our portfolio, pipeline and career opportunities.

Contact Us